NEW YORK, April 10, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Edwards Lifesciences Corp (NYSE: EW), Alkermes Plc (NASDAQ: ALKS),
ResMed Inc. (NYSE: RMD), Auxilium Pharmaceuticals, Inc. (NASDAQ:
AUXL), and Teleflex Incorporated (NYSE: TFX). Private wealth
members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
Edwards Lifesciences Corp Analyst Notes
On April 4, 2014, Edwards
Lifesciences Corp (Edwards Lifesciences) announced that its
advanced EDWARDS INTUITY Elite valve system has received CE Mark.
According to the Company, this next-generation valve system
combines a unique balloon-expandable frame with Edwards' proven
pericardial PERIMOUNT platform, and has design improvements
intended to improve ease of use, including a flexible and lower
profile delivery system that is designed to facilitate access and
visibility through smaller incisions. Prof. Michael Borger, M.D. Ph.D., Associate Director
of the Department of Cardiac Surgery at the Leipzig Heart Center in
Germany, commented, "We're
encouraged by the introduction of heart valve technologies that are
developed to facilitate a minimally invasive approach for the
improved treatment of patients with aortic valve disease. Our
experience with the EDWARDS INTUITY platform has shown the ability
to implant the valve through smaller incisions, with significantly
reduced cross-clamp time and improved hemodynamics. This
less-invasive, more efficient surgical approach should benefit
patients during and after their procedure." The full analyst notes
on Edwards Lifesciences Corp are available to download free of
charge at:
http://www.AnalystsReview.com/04102014/EW/report.pdf
Alkermes Plc Analyst Notes
On April 7, 2014, Alkermes Plc's
(Alkermes) stock slipped 1.04% to close at $41.10. Over the past three months of trading,
Alkermes' stock gained 1.58% while the Nasdaq Composite declined
1.77% during the same period. The full analyst notes on Alkermes
Plc are available to download free of charge at:
http://www.AnalystsReview.com/04102014/ALKS/report.pdf
ResMed Inc. Analyst Notes
On March 25, 2014, ResMed Inc.
(ResMed) announced that it has scheduled the release of its Q3 FY
2014 and 9M FY 2014 results (period ended March 31, 2014) on Wednesday, April 23, 2014, after 1:00 p.m. PT. The Company added that a conference
call will follow at 1:30 p.m. PT on
the same day to review the results, market trends, and future
outlook. ResMed stated that the call can be accessed at the Company
website, where an archive will be made available for 2 weeks after
the call. The full analyst notes on ResMed Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/04102014/RMD/report.pdf
Auxilium Pharmaceuticals, Inc. Analyst Notes
On April 7, 2014, Auxilium
Pharmaceuticals, Inc. (Auxilium), along with Swedish Orphan
Biovitrum AB (Sobi), announced that Sobi is now the Market
Authorisation Holder (MAH) for Xiapex® (collagenase clostridium
histolyticum), in 28 EU member countries, Norway, and Iceland on April 3,
2014. According to the Company, Sobi, if it chooses to do
so, may now file for market authorization for Xiapex for the
treatment of Peyronie's disease and work is ongoing for that filing
in the EU. Auxilium stated that Sobi holds the exclusive rights to
commercialise Xiapex for the Dupuytren's contracture and Peyronie's
disease indications, in these countries subject to applicable
regulatory approvals. Auxilium informed that Xiapex/ XIAFLEX® is a
first-in-class biologic approved in the US, EU, Canada and Australia for the treatment of adult patients
of Dupuytren's contracture - a progressive condition affecting the
hand -with a palpable cord and in the US for the treatment of adult
men with Peyronie's disease with a palpable plaque and curvature
deformity of at least 30 degrees at the start of therapy. The full
analyst notes on Auxilium Pharmaceuticals, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/04102014/AUXL/report.pdf
Teleflex Incorporated Analyst Notes
On April 7, 2014, shares in
Teleflex Incorporated (Teleflex) dropped 1.12% or by 1.19 points to
close trading at $105.47. Shares in
Teleflex increased over the past six months of trading by 28.08%,
in comparison with the Nasdaq Composite which gained 8.21% during
the same period. The full analyst notes on Teleflex Incorporated
are available to download free of charge at:
http://www.AnalystsReview.com/04102014/TFX/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.AnalystsReview.com/
SOURCE Analysts Review